description="lightestColor"> href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=37&F=H"> src="http://www.shareholdervision.com/guru-email/g/logo-wide.jpg"
border="0" height="77" width="700" />

You are
subscribed as Subscriber

Breaking News:
Vicor Technologies, Inc. (OTCBB: VCRT)

width="223" />

Vicor Technologies, Inc. (OTCBB: VCRT)

Vicor Technologies Announces Extensive Collaborative Agreement With
the Universidad San Francisco de Quito in Ecuador

Feb 23, 2010 8:30:00 AM

BOCA RATON, FL — (MARKET WIRE) — 02/23/10 — David H. Fater, CEO of
Vicor Technologies, Inc. (OTCBB: VCRT), today announced that the Company
has entered into a collaborative agreement with the Universidad San
Francisco de Quito in Ecuador to further awareness and use of the measure
of heart rate variability as a medical diagnostic. Vicor Technologies is a
biotechnology company focused on the commercialization of innovative,
non-invasive medical devices and diagnostics using its patented,
proprietary PD2i® nonlinear algorithm and software to stratify patients
at risk of sudden cardiac death and autonomic nervous system dysfunction,
and trauma victims in need of lifesaving intervention.

Vicor’s PD2i Analyzer™ displays and analyzes electrocardiographic data
to provide a measure of heart rate variability (HRV) in patients at rest,
and during controlled exercise and paced respiration. The clinical
significance of HRV is physician determined. Under the terms of the
agreement Vicor will collaborate with the Universidad San Francisco de
Quito (USFQ) to:

– develop academic programs that advance awareness and use of the
measure
of heart rate variability (HRV) to diagnose various medical
disorders
within a variety of health-challenged and/or at risk
populations,
— promote continued research into the uses of HRV in
USFQ clinics, and
— stimulate assistance from Ecuador’s public and
private health sectors
with the goal of preventing disease with
appropriate
intervention/treatment based on early diagnosis using
HRV.

Additionally, Vicor will serve as the sponsor of the Vicor
Technologies, Inc. Heart Rate Variability Institute at the Universidad San
Francisco de Quito, with the express purpose of furthering throughout
Ecuador HRV research and its use as a medical diagnostic as measured with
Vicor’s PD2i Analyzer™.

Specifically, this collaboration will involve the Inclusion Institute,
its emergency rooms, and intensive care units for applications involving
patients at imminent risk of death, those with severe psychiatric illness,
and those with elevated cardiovascular risk and mental illness.

This effort may also include study of HRV as measured by Vicor’s PD2i
Analyzer™ to identify autonomic nervous system dysfunction in diabetics,
the need for lifesaving intervention in trauma victims as a means of
facilitating triage efforts, imminent mortality in those with brain injury,
and the risk of sudden cardiac death in target populations, including young
athletes.

“Science and technology have propelled knowledge and practical
applications in medicine at a fantastic speed. The collaboration of several
universities for the purpose of investigating the risk of sudden death in
certain special groups will definitely broaden the spectrum of routine
procedures that will result in the prevention of these events and the
salvage of precious human lives,” stated Dr. Enrique Noboa, Dean, USFQ
School of Medicine.

“Autonomic nervous system dysfunction and its role in disease
constitute a field of continuous expansion and research. The implications
of heart rate variability analysis involve several disciplines, and focus
our attention in multi-causality. Furthermore, the rapid, precise,
non-invasive and cost-effective stratification of risk of AD in patients
admitted to the Emergency Department with the PD2i® test is invaluable.
I welcome Vicor’s initiative involving the identification of autonomic
nervous system dysfunction, and the research and application of heart rate
variability analysis, as important components in the promotion of health,
prevention of disease, and as a means of providing immediate response and
intervention in life threatening scenarios,” stated Dr. Michelle Grunauer,
Project Manager, USFQ HRV Institute.

“We are extremely pleased and honored to be selected for such a
significant collaboration with the Universidad San Francisco de Quito, a
private university with a first class international reputation that
attracts outstanding educators. We’re especially excited about furthering
awareness of the measure of HRV as a diagnostic in general, and for
identifying autonomic nervous system dysfunction, trauma severity, and the
risk of sudden cardiac death. Most importantly, USFQ has two campuses and
research facilities, as well as clinics throughout Ecuador, which will
enable the outcomes of our collaborative efforts to benefit Ecuadorians
throughout the country,” stated Mr. Fater.

The Universidad San Francisco de Quito is a non-profit liberal arts
university. Founded in 1988 by the Corporación de Promoción
Universitaria, (its umbrella non-profit foundation), the USFQ was the first
totally private, self-financed university in Ecuador. Today, the USFQ has
sixteen Colleges and Academic Institutes spread across its main campus in
Cumbayá-Quito and The Galapagos Academic Institute for the Arts and
Sciences in San Cristobal in the Galapagos Archipelago. Additionally, USFQ
has a biodiversity research station in Tiputini and an anthropology
research institute in Riobamba.

About Vicor Technologies, Inc.

Vicor Technologies is a biotechnology company creating innovative
non-invasive diagnostics employing its patented, proprietary point
correlation dimension algorithm (PD2i®). The PD2i® nonlinear
algorithm is a deterministic, nonlinear measure of electrophysiological
potentials that predicts future pathological events with a high degree of
accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear
algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance,
measures heart rate variability; physicians performing diagnostic tests
with the PD2i Analyzer™ are able to receive reimbursement under existing
CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a
collaborative effort with the U.S. Army Institute for Surgical Research
(http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian
trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical
trials, identifies patients at risk of sudden cardiac death.

Vicor anticipates additional applications employing the PD2i®
nonlinear algorithm to enable early detection and risk stratification for a
variety of other disorders and diseases. Additional information is
available at www.vicortech.com.

The appearance of name-brand institutions or products in this media
release does not constitute endorsement by the U.S. Army Medical Research
and Materiel Command, the Department of the Army, Department of Defense or
the U.S. Government of the information, products or services contained
therein.

Caution Regarding Forward-Looking Statements

Forward-looking statements in this press release are based on current
plans and expectations that are subject to uncertainties and risks, which
could cause our future results to differ materially. The following factors,
among others, could cause our actual results to differ: our ability to
obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian
applications and the PD2i CA™(Cardiac Analyzer), our ability to continue
to receive financing sufficient to continue operations and complete the
critical clinical trials; our ability to continue as a going concern; our
ability to successfully develop products based on our technologies,
included but not limited to our ASP distribution model for the PD2i
Analyzer™; our ability to obtain and maintain adequate levels of
third-party reimbursement for our products; the impact of competitive
products and pricing; our ability to receive regulatory approval for our
products; the ability of third-party contract research organizations to
perform preclinical testing and clinical trials for our technologies; the
ability of third-party manufacturers to manufacture our products; our
ability to retain the services of our key personnel; our ability to market
and sell our products successfully; our ability to protect our intellectual
property; product liability; changes in federal income tax laws and
regulations; general market conditions in the medical device and
pharmaceutical industries; and other matters that are described in Vicor’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and
subsequent filings with the Securities and Exchange Commission.
Forward-looking statements in this press release speak only as of the date
of the press release, and we assume no obligation to update forward-looking
statements or the reasons why actual results could differ.

Release 10-03

Add to Digg Bookmark with del.icio.us Add to Newsvine

CORPORATE CONTACT
David H. Fater
Vicor Technologies,
Inc.
561.995.7313
dfater@vicortech.com

INVESTOR CONTACT
Richard Moyer
Cameron Associates
212.554.5466
richard@cameronassoc.com

MEDIA CONTACT
Robin Schoen
Robin Schoen Public Relations /> 215.504.2122
schoenpr@comcast.net

width="223" />

Vicor Technologies, Inc. (OTCBB: VCRT)

Introduction

Vicor Technologies, Inc. (OTCBB: VCRT) is in the crucial
transformative stage for a biotechnology company on the verge of becoming
a viable commercial enterprise.

This biotechnology company is focused on the commercialization of
innovative, non-invasive medical devices and diagnostics using its
patented, proprietary PD2i™ nonlinear algorithm and software which
is:

• Highly accurate
• Provides user friendly data acquisition
• Effective for trauma triage easily deployed in a portable
  monitor
• Provides a simple noninvasive test for identifying patients at risk of
  sudden cardiac death
• Provides a simple noninvasive test for identifying patients with
  Diabetic Autonomic Neuropathy

width="127" />The PD2i Algorithm and software risk stratifies target
populations to predict future pathological events. As a predictor of
sudden cardiac death it has been shown to be highly accurate, with a
sensitivity approaching 100% and a specificity of ~86%.

The advantage of the PD2i™ nonlinear algorithm is that it
typically uses recordings made at rest and does not require stress-testing
or any active participation from the patient. The test is relatively
impervious to data non-stationarities and artifacts, setting it apart from
other measures with unparalleled sensitivity.

A large physician shareholder base represents the early adoptees of
this Company.

Vicor’s PD2i™ Nonlinear Algorithm is:

• A new vital sign with the ability to actually save lives in both
  combat and civilian setting
• The PD2i Analyzer™ can capture and display Heart Rate
  Variability (see defined below) in patients at rest and during paced
  respiration and controlled exercise.
• Able to identify trauma victims in need of an immediate lifesaving
  intervention
• Able to be used along with other clinical data to identify patients at
  risk of sudden cardiac death
• Able to be used along with other clinical data to identify patients
  who have autonomic dysfunction
• Able to improve trauma triage in real world situations and on the
  battlefield where time is of the essence and the collection of
  ‘clean’ data is never guaranteed
• Able to provide consistently accurate results which requires just one
  to two minutes of EKG data in a trauma setting
• Not derailed in delivering actionable results by noisy raw EKG
  data
• Functional in trauma environments and battlefield situations

READ THE FULL STOCKGURU PROFILE HERE:

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=947&F=H">http://www.stockguru.com/about/vicor/

Live
Twitter Alerts All Market Day

Our
Twitter Feed includes all live posts from StockGuru.com.

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=141&F=H"> src="http://www.stockguru.com/l/twitter-163w.gif" border="0" />

Featured
on StockGuru

While
we cover many companies, here are our current featured profiles
on StockGuru:

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=1086&F=H"
style="color: #576164">Hi Score Corporation.
(OTC:
HSCO)

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=1086&F=H"
style="color: #576164">Halo Companies, Inc..
(OTCBB:
GPAX)

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=980&F=H"
style="color: #576164">Diagnostic Imaging
International Corp.
(OTCBB: DIIG)

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=947&F=H"
style="color: #576164">Vicor Technologies, Inc.
(OTCBB:
VCRT)

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=1094&F=H"
style="color: #576164">Medizone International
(OTCBB: MZEI)

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=1093&F=H"
style="color: #576164">Skinvisible, Inc.
(OTCBB: SKVI)

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=666&F=H"> src="http://www.boldstocks.com/images/BOLD-163-178.gif" border="0"
height="178" width="163" />

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=3&F=H"
style="color: #576164"> href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=204&F=H"> src="http://www.stockguru.com/l/china/china-163-wide.gif" border="0"
height="155" width="163" />

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=1&F=H"
style="color: #576164">

StockGuru
Spotlight Alerts

Here
are our latest Spotlight Alerts. Note that we typically
do NOT email these to members. You must visit the site at href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=4&F=H"
style="color: #576164">THIS LINK to keep up to
date; or you may subscribe to href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=706&L=2&F=H"
style="color: #576164">THIS RSS
FEED.

Suggest
a Client:

Do you
know a great company that simply must be featured on
StockGuru or Shareholder Vision?

Suggest it
to us.

Email: href="mailto:john@stockguru.com" style="color:
#576164">john@stockguru.com
Tel: (469) 252-3031.